The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid

Seizure

Volumn 16, Issue 1, 2007, Pages 43-49

  Tong, X ^a   Ratnaraj, N ^a   Patsalos, P N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drug; Blood; Cerebrospinal fluid; Pharmacokinetics; Vigabatrin

Indexed keywords

VIGABATRIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG ELIMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; ANTICONVULSANTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, SPRAGUE-DAWLEY; VIGABATRIN;

EID: 33845503686     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2006.10.003     Document Type: Article

References (36)

1. Sander J.W. The use of antiepileptic drugs-principles and practice. Epilepsia 45 Suppl. 6 (2004) 28-34
2. Loiseau P., Hardenberg J.P., Pestre M., et al. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug resistant epilepsy. Epilepsia 27 (1986) 115-120
3. Dean C., Mosier M., and Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 40 (1999) 74-82
4. Appleton R.E., Peters A.C., Mumford J.P., et al. Randomized, placebo-controlled study of vigabatrin in first-line treatment of infantile spasms. Epilepsia 40 (1999) 1627-1633
5. Vigevano F., and Cilio M.R. Vigabatrin versus ACTH as first-line treatment of infantile spasms: a randomized prospective study. Epilepsia 38 (1997) 1270-1274
6. Nousiainen I., Mantyjarvi M., and Kalviainen R. No reversion in vigabatrin-associated visual field defects. Neurology 57 (2001) 1916-1917
7. Toggweiler S., and Wieser H.G. Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 10 (2001) 420-423
8. Malmgren K., Ben-Menachem E., and Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 42 (2001) 609-615
9. McDonagh J., Stephen L.J., Dolan F.M., et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61 (2003) 1690-1694
10. Bernasconi R., Klein M., Martin P., et al. γ-Vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice. J Neural Transmit 72 (1988) 213-233
11. Chapman A.G., De Sarro G.R., Premachandra M., and Meldrum B.S. Bidirectional effects of β-carbolines in reflex epilepsy. Brain Res Bull 19 (1987) 337-346
12. Schechter P.J., Tranier Y., Jung M.J., and Bohlen P. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of γ-acetylenic GABA and γ-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 45 (1977) 319-328
13. Lippert B., Metcalf B.W., Jung M.J., and Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotrasferase in mammalian brain. Eur J Biochem 74 (1997) 441-445
14. De Biase D., Barra D., Bossa F., et al. Chemistry of the inactivation of 4-aminobutyrate aminotransferase by the antiepileptic drug vigabatrin. J Biol Chem 266 (1991) 20056-20061
15. Gale K., and Iadarola M.J. Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition. Science 208 (1980) 288
16. Rey E., Pons G., and Olive G. Vigabatrin: clinical pharmacokinetics. Clin Pharmacokinet 23 (1992) 267-278
17. Valdizan E.M., Garcia A.P., and Armijo J.A. Time course of the GABAergic effects of vigabatrin: Is the time course of brain GABA related to platelet GABA-transaminase inhibition?. Epilepsia 40 (1999) 1062-1069
18. Sills G.J., Butler E., Forrest G., et al. Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44 (2003) 886-892
19. Sills G.J., Patsalos P.N., Butler E., et al. Visual field constriction. Accumulation of vigabatrin but not tiagabine in the retina. Neurology 57 (2001) 196-200
20. Halonen T., Pitkanen A., and Riekkinen P.J. Administration of vigabatrin (γ-vinyl-γ-aminobutyric acid) affects levels of both inhibitory and excitatory amino acids in rat cerebrospinal fluid. J Neurochem 55 (1990) 1870-1874
21. Jung M.J., Lippert B., Metcalf B.W., et al. γ-vinyl GABA (4-amino-hex-5-enoic), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 29 (1977) 797-802
22. Halonen T., Pitkanen A., Saano V., and Riekkinen P.J. Effect of vigabatrin (γ-vinyl GABA) on neurotransmission-related amino acids and on GABA and benzodiazepine receptor binding in rats. Epilepsia 32 (1991) 242-249
23. Ben-Menachem E. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans. Epilepsia 30 Suppl. 3 (1989) S12-S14
24. Ben-Menachem E., Persson L.I., Schechter P.J., et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 27 (1989) 79S-85S
25. Riekkinen P.J., Pitkanen A., Ylinen A., et al. Specificity of vigabatrin for the GABAergic system in human epilepsy. Epilepsia 30 Suppl. 3 (1989) S18-S22
26. Danhof M., and Levy G. Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmocol Exp Ther 229 (1984) 44-50
27. Dingemanse J., van Bree J.B.M.M., and Danhof M. Pharmacokinetic modelling of the anticonvulsant action of phenobarbital in rats. J Pharmacol Exp Ther 249 (1987) 601-608
28. Klockowski P.M., and Levy G. Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats. J Pharmacol Exp Ther 244 (1988) 912-918
29. Sokomba E.N., Patsalos P.N., Lolin Y.I., and Curzon G. Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid. Neuropharmacology 27 (1988) 409-415
30. De Lange E.C.M., and Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting. Clin Pharmacokinet 41 (2002) 691-703
31. Patsalos P.N., Alavijeh M.S., Semba J., and Lolin Y.I. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. J Pharmacol Toxicol Methods 28 (1992) 21-28
32. Walker M.C., Tong X., Perry H., Alavijeh M.S., and Patsalos P.N. Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br J Pharmacol 130 (2000) 242-248
33. Wang X., and Patsalos P.N. A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin or fosphenytoin. Seizure 12 (2003) 330-336
34. Ratnaraj N., and Patsalos P.N. A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther Drug Monit 20 (1998) 430-434
35. Wang X., Ratnaraj N., and Patsalos P.N. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus. Seizure 13 (2004) 574-581
36. Nagaki S., Ratnaraj N., and Patsalos P.N. Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide, in the rat. Eur J Drug Metab Pharmacokinet 24 (1999) 255-264